AngioDynamics (NASDAQ: $ANGO) is a healthcare company that designs, makes, and sells medical equipment. It specializes in devices used for minimally invasive vascular access, surgery, for peripheral vascular disease, and oncology. On Tuesday, January 6, 2026, it released its Q2 fiscal 2026 results. Let us dive into those results.
AngioDynamics Q2 Results
For the second quarter, AngioDynamics reported revenue of $79.4 million, an 8.8% YoY increase, and above forecasts of $76.43 million. It reported an adjusted loss per share of $0.00, beating forecasts of a $0.22 loss per share.
The Med Tech unit delivered revenue of $35.7 million, a 13% YoY increase, while the Med Device segment delivered revenue of $43.8 million, a 5.6% YoY increase. It ended Q2 with $41.6 million in cash and cash equivalents, beating its own forecasts.
Other Highlights
In Q2, AngioDynamics announced that the FDA approved its Investigational Device Exemption (IDE) application for the PAVE clinical study. It also revealed that it had received FDA 510(k) clearance for a modified AlphaVac F1885 System with expanded indications for use.
The success of its Q2 results was attributed to the robust growth of its Med Tech division. Jim Clemmer, the company’s CEO, stated that their strategic shift to innovative platform technologies had been positive. He noted that products like Mechanical Thrombectomy, NanoKnife, and Auryon were gaining traction.
The company revealed that it expects current CEO Clemmer to retire when it names a successor, which is expected to occur during fiscal 2027.
Fiscal 2026 Guidance
The company revised its fiscal 2026 net sales guidance upwards to $312-$314 million from the previous forecast of $308 – $313 million. It expects its Med Tech net sales to rise 14%-16% YoY, and Med Devices net sales to grow 0%-1%, up from the previous forecast of flat growth.
The company expects a gross margin of 53.5%-55.5%, unchanged from its previous guidance. It now expects a full-year adjusted EBITDA of $8-10 million, up from the previous forecast of $6-$10 million. For the full year, it continues to expect an adjusted EPS loss of $0.33-$0.23. The company also expects to end fiscal 2026 with positive free cash flow.
Market Performance
Despite raising full-year guidance and beating forecasts, ANGO shares dipped 14.21% to $11.35 as of 2:10 PM in New York. Year to date, the stock is down 11.45%, while over the past six months, the stock is up 18.68%. The stock is also up 22.65% over the past 12 months. Before today’s leadership change news, the stock was up 40%+ in the past six months as of Monday’s close.
The current price is below its 50-day moving average of $12.65, but above its 200-day moving average of $10.60. 6.44% of the shares are held by insiders, while institutional investors hold 95.92% of the stock, which signals trust in the long-term trajectory of the company.
Analysts are optimistic about the future of $ANGO shares, giving them an overall strong buy rating. They forecast an average price of $19.33, which is a 63.54% upside. The analysts give a wide range of price forecasts, with a low of $16 and a high of $24.
Is AngioDynamics A Buy In 2026?
Overall, AngioDynamics is making strategic moves to improve its market position and product offerings. It has also had a lot of success with FDA approvals. However, the leadership change announcement caused some jitters amongst investors. Nevertheless, the long-term trajectory of the company looks promising. As such, adding $ANGO shares to your portfolio could potentially be a great long-term play.
Click Here for Updates on ANGO – It’s 100% FREE to Sign Up for Text Message Notifications!
Disclaimer: This website provides information about cryptocurrency and stock market investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for educational and informational purposes only. The owner of this website is not a registered investment advisor and does not offer investment advice. You, the reader / viewer, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Please read our Full Disclaimer: https://dexwirenews.com/disclaimer/
